# ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

> **NCT01110473** · PHASE1 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 52 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Myelogenous Leukemia
- B-cell Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplasia

## Interventions

- **DRUG:** ABT-348
- **DRUG:** ABT-348
- **DRUG:** ABT-348 and azacitidine
- **DRUG:** ABT-348

## Key facts

- **NCT ID:** NCT01110473
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110473, "ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01110473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*